Considering the potential importance of NR2F1 in regulating tumor latency and melanoma MRD, diving even deeper into mechanism(s) of action will provide additional opportunities to develop creative and potentially effective therapies in treating residual and therapy-refractive disease. This evidence concerns the gene NR2F1 and melanoma.